| 1.76 -0.11 (-5.88%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.2 |
1-year : | 4.02 |
| Resists | First : | 2.74 |
Second : | 3.45 |
| Pivot price | 1.88 |
|||
| Supports | First : | 1.6 | Second : | 1.33 |
| MAs | MA(5) : | 1.74  |
MA(20) : | 2.1 |
| MA(100) : | 4.57 |
MA(250) : | 5.14 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 21 |
D(3) : | 14.6 |
| RSI | RSI(14): 26.3 |
|||
| 52-week | High : | 8.59 | Low : | 1.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRBU ] has closed above bottom band by 29.3%. Bollinger Bands are 63.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.87 - 1.88 | 1.88 - 1.89 |
| Low: | 1.71 - 1.72 | 1.72 - 1.73 |
| Close: | 1.74 - 1.76 | 1.76 - 1.78 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Mon, 24 Jun 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc ... - PR Newswire
Wed, 19 Jun 2024
Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Update - Defense World
Mon, 17 Jun 2024
Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Update - MarketBeat
Wed, 05 Jun 2024
Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding - Simply Wall St
Mon, 03 Jun 2024
Citi reiterates 'Buy' on Caribou Biosciences stock, citing promising HLA-matching results By Investing.com - Investing.com
Sun, 02 Jun 2024
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 6.903e+007 (%) |
| Held by Institutions | 10 (%) |
| Shares Short | 11,340 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.273e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 893.8 % |
| Return on Equity (ttm) | -21.8 % |
| Qtrly Rev. Growth | 3.34e+007 % |
| Gross Profit (p.s.) | -12.6 |
| Sales Per Share | -15.27 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -103 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.12 |
| Price to Cash Flow | 1.12 |
| Dividend | 0 |
| Forward Dividend | 1.049e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|